Arcturus Therapeutics drops 7% as Q4 results disappoint

mohd izzuan Arcturus Therapeutics ( NASDAQ: ARCT ) is down ~7% in after-hours trading Thursday after posting Q4 2024 financial results that missed on both lines . In the quarter, loss per share, basic and diluted, dropped to -$1.11 from -$0.

44 in the year-ago period. Arcturus.